IXAZOMIB COMBINATION REJECTED FOR MULTIPLE MYELOMA

摘要

NICE has again rejected ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone (IRd) for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more previous therapies. After NICE initially rejected ixazomib, manufacturer Takeda proposed a price reduction for it to be included in the Cancer Drugs Fund, but the appraisal committee considered that ixazomib was still unlikely to be cost effective.